- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07942038
Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI
Myocardial Tissue Characterization and Deformation Kinetics Following the Ross Procedure: A Prospective Multiparametric CMR Study
The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.
Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.
This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.
Beschreibung
Inclusion Criteria:
- Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
- Informed written consent to participate in serial prospective imaging.
Exclusion Criteria:
- Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
- Prior myocardial infarction or primary non-ischemic cardiomyopathy.
- Severe renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m²).
- Associated congenital heart disease causing volume overload ex: VSD and PDA.
- Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
- Standard contraindications to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diffuse myocardial fibrosis
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Diffuse myocardial fibrosis
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Subclinical myocardial mechanical recovery
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by global radial strain [GRS]. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Zeitfenster: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- CMR-ROSS
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .